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Background: Previous studies have profiled breast cancer compared to normal breast tissue and identified
differentially expressed microRNAs (miRNAs). These miRNAs are then assessed in serum of breast cancer patients
compared to healthy volunteers. MiRNAs in serum however do not always reflect what is in tissue and important
serum miRNAs may be missed. PCR arrays were therefore performed on serum samples from breast cancer patients
compared to healthy volunteers with the aim of identifying circulating miRNAs that are more highly expressed in
serum from early breast cancer patients compared to controls.
Methods: Taqman low density array (TLDA) cards were used to profile serum miRNAs in a discovery cohort of
serum from 39 early breast cancer patients compared to 10 healthy volunteers. The results were confirmed in a
validation cohort of serum from 98 early breast cancer patients compared to 25 healthy volunteers using
customized qPCR plates.
Results: Seventeen miRNAs were found to have significantly higher levels in breast cancer serum compared to
serum of healthy volunteers in the discovery cohort. Fourteen of these miRNAs were studied in the validation
cohort and serum miR-484 was found to be at a significantly higher level in breast cancer serum compared to
healthy volunteers.
Conclusion: In this study, we found that miR-484 is significantly differentially expressed in serum of early breast
cancer patients compared to healthy volunteers. We did not however find any correlation between miR-484 levels
with histopathological parameters of the breast cancers. With further studies, miR-484 may prove useful as an
adjunct to mammography for detection of early breast cancer.
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MicroRNAs (miRNAs) are 21–25 nucleotide non-coding
RNAs that negatively regulate gene expression in a se-
quence specific manner at a post-transcriptional level.
Each miRNA controls the expression of multiple target
genes, by binding to the 3’ untranslated region of target
mRNAs to induce degradation of the message or inhib-
ition of translation. Hence, miRNA expression can have* Correspondence: p.soon@unsw.edu.au
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unless otherwise stated.a dramatic impact on cellular phenotype and function [1].
To date, there are 2578 miRNA transcripts in humans [2]
with wide-ranging roles, including development, differen-
tiation, growth and apoptosis [3].
MiRNAs have also been implicated in cancer. These
miRNAs, termed ‘oncomirs’, can act in a fashion analo-
gous to tumor suppressor genes or oncogenes. A number
of miRNAs have been found to be implicated in breast
cancer [4]. MiRNA expression profile has also been re-
ported to be associated with pathological features of
breast cancer, such as tumor size, lymph node positivity,
presence of vascular invasion and hormone receptortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Zearo et al. BMC Cancer 2014, 14:200 Page 2 of 7
http://www.biomedcentral.com/1471-2407/14/200status indicating that miRNAs may play a role in defining
the differences between these pathological profiles [4].
MiRNAs have been found to be present in bodily fluids
[5]. They are stable in serum and appear to be protected
from RNase activity. They also appear to be stable under
extreme conditions which include boiling temperatures,
low and high pH, multiple freeze/thaw cycles and storage
for prolonged periods [6]. Serum miRNAs are therefore
ideal as biomarkers.
A number of papers have reported that circulating
miRNAs are able to distinguish serum from cancer pa-
tients compared to controls. Mitchell et al. demonstrated
that serum levels of miR-141 were able to distinguish
metastatic prostate cancer patients from healthy controls
[7]. Serum levels of miR-299-5p and miR-411 have been
reported to be significantly lower in breast cancer pa-
tients compared to healthy controls. For patients with
metastatic breast cancer, it was noted that treatment
resulted in an increase in the levels of these miRNAs
approaching those of healthy controls [8].
Previous studies have profiled breast cancer compared
to normal breast tissue and identified differentially
expressed miRNAs. These miRNAs are then assessed in
serum of breast cancer patients compared to healthy
volunteers. MiRNAs in serum however do not always re-
flect what is in tissue and important serum miRNAs
may be missed. We therefore decided to perform PCR
arrays of serum samples from breast cancer patients
compared to healthy volunteers. The aim of this paper
was two-fold: 1) to identify circulating miRNAs that are
found at higher levels in serum from early breast cancer
patients compared to controls; these miRNAs may then
be potentially used as serum biomarkers for identifying
breast cancer patients and 2) to determine if expression
of these circulating miRNAs are markers of clinical out-
come such as pathological criteria and axillary lymph
node status in breast cancer.
Methods
Patient serum samples
Ethics approval for the study was obtained from the
Northern Sydney and Central Coast Area Health Service
Human Research Ethics Committee, Sydney, Australia.
Serum samples were obtained from the Kolling Breast
Tissue Bank and Australian Breast Cancer Tissue Bank.
The discovery cohort consisted of serum samples from
39 breast cancer patients and 10 healthy volunteers,
while the validation cohort consisted of serum samples
from 98 breast cancer patients and 25 healthy volun-
teers. All the breast cancer patients had operable breast
cancer with no evidence of metastasis on staging investiga-
tions and who had not undergone neoadjuvant chemother-
apy. For the breast cancer patients, blood was collected
into a Vacuette serum clot activator gel free tube whenthey attended the preadmission clinic 2–4 weeks prior to
the surgery or while they were in the anaesthetic bay, prior
to their general anaesthetic and surgery. The blood in the
tube was kept on ice for 15–30 minutes, then centrifuged
for 15 minutes at 3000 rpm at 4°C. The serum was then
divided into 1.5 mls cryovials in 500 μl aliquots and stored
at -80°C. For healthy volunteers, blood was collected from
patients at the menopause clinic into Vacuette serum clot
activator gel free tubes, and processed and stored as per
the protocol described above.
RNA extraction
Small RNA was extracted from 200 μl of serum using
the miRvana™ PARIS™ kit as per the manufacturer’s
instructions. The quality of RNA was assessed using the
Nanodrop spectrophotometer.
Taqman low density array (TLDA) MicroRNA analysis
MiRNA profiling was performed with the TaqMan®
Array Human MicroRNA Cards A and B v3.0 as per the
manufacturer’s protocol, with each card quantitating 377
miRNAs. Briefly, 30 ng of RNA was initially reverse tran-
scribed using the Megaplex RT Primers Pools A and B
followed by pre-amplification with Megaplex Pre-amp
Primers Pools A and B, and 800 μl of the pre-amplification
product was then loaded on the TaqMan® Array Human
MicroRNA Card and run on the AB7900HT. Preamplifica-
tion has been shown by Mestdagh et al. to be sensitive and
reliable without introducing bias [9].
Data analysis was performed using RQ Manager 1.2.1,
DataAssist v3.0 and qBasePlus. MiRNAs with a CT
value > 37 were considered unamplified. MiRNAs in which
more than 12 samples were not amplified were considered
to be lowly expressed and therefore excluded, resulting
in 88 miRNAs being included in the analysis. Global
normalization was performed. Additional analyses were
performed using miR-16 for normalization with similar
results.
Quantitative reverse transcription polymerase chain
reaction (qPCR) validation
Validation of the TLDA findings was performed by
qPCR using TaqMan® Custom 384-well Plates on which
the following TaqMan® miRNA assays were pre-plated in
triplicate: hsa-miR-16, U6 snRNA, hsa-miR-186, hsa-
miR-484, hsa-miR-29a, hsa-miR-425-5p, hsa-miR-454,
hsa-miR-574-3p, hsa-miR-140-3p, hsa-miR-222, hsa-let-
7b, hsa-miR-483-5p, hsa-miR-21, hsa-miR-195, hsa-miR-
155, hsa-miR-218. Global normalization was performed.
Additional analyses were also performed using miR-16
for normalization with similar results. Thirty ng of RNA
was reverse transcribed using Custom RT primer pool
then pre-amplified using Custom PreAmp primer
Pool and 100 μl of pre-amp product was then loaded
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8 samples.
Tissue
Twelve breast cancer fresh frozen tissue and the corre-
sponding normal breast tissue were obtained from the
Kolling Breast Tissue Bank. qPCR assessment of hsa-miR-
484, hsa-miR-21, hsa-miR-16 and U6 snRNA was per-
formed on the AB7900 in triplicate.
Statistical analysis
The microarray data was analyzed using t-test and
Bonferroni correction for false discovery rate such that
differential expression was considered to be significant
with a p < 0.0001. The data was analyzed using QBase-
Plus and Data Assist. For the discovery and validation
cohorts, normalization was performed using global
normalization. For tissue, normalization was performed
using U6, a common housekeeper used for tissue but
not expressed in serum. All other statistical analyses
were performed with SPSS 16 for Windows and a p <
0.05 was considered significant. Categorical data were
analysed using Fisher’s exact test. The Mann–Whitney
test was used for qPCR statistical analysis because the
data were not normally distributed and were heteroske-
dastic, despite attempted data transformation.
Results
A mean of 544 ± 499 ng of RNA was extracted from the
serum samples.
Discovery cohort
Serum samples from 39 early breast cancer patients and
10 healthy volunteers were used for miRNA expression
profiling. The clinical characteristics of the breast cancer
patients and the pathology of the cancers are listed in
Table 1.Table 1 Clinical characteristics of the healthy volunteers, brea





Number of patients 39 10
Age (mean ± SD) 58 ± 16 60 ± 6
Subtype of cancer 39 IDC
Size of invasive cancer (mm) 30.5 ± 25.2
Lymph node negative (%) 19 (48.7%)
Number of positive axillary lymph nodes 3.0 ± 6.4
ER positive 28 (71.8%)
PR positive 22 (56.4%)
HER2 positive 6 (15.4%)
Abbreviations: IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma.PCR array analysis
In this study, RNA extracted from serum of both cancer
patients and healthy volunteers had to be pre-amplified
in order to increase the limit of miRNA detection. Pre-
amplification of RNA samples has been done by others
with good correlation of quantitative PCR results using
RNA that has and has not been preamplified [9].
Comparison of cancer versus normal serum identified
17 significantly up-regulated miRNAs with corrected
p-value <0.05 and foldchange >2 (Table 2).
Validation cohort
Our validation cohort consisted of serum from 98 early
breast cancer patients and 25 healthy volunteers. The
clinical characteristics of the breast cancer patients and
pathology of the cancers are listed in Table 1. We per-
formed qPCR using custom TaqMan® 384-well Plates on
14 miRNAs. We assessed the serum levels of hsa-miR-186,
hsa-miR-484, hsa-miR-29a, hsa-miR-425-5p, hsa-miR-454,
hsa-miR-574-3p, hsa-miR-140-3p, hsa-miR-222, hsa-let-7b
and hsa-miR-483-5p because these miRNAs were sig-
nificantly over-expressed in breast cancer serum com-
pared to healthy serum in the discovery cohort. We
chose to assess miR-21 because it is known to be widely
over-expressed in cancer versus normal [4,10]. There is lit-
erature of increased serum levels of miR-195 in breast
cancer patients [11] and miR-155 has a known role in
breast cancer tumorigenesis [12]. miR-16 was used as one
of the methods of normalization.
Of the 14 miRNAs assessed, we found that five of
the miRNAs were significantly differentially expressed
in breast cancer compared to healthy serum (Table 3).
We noted that miR-16 was not differentially expressed
between cancer and normal serum with mean expres-
sion level in cancer serum of 1.001 and 0.994 in normal
serum. We did not find a difference in the level of serum
miRNA between patients with invasive ductal carcinomast cancer patients and pathological characteristics of







55 ± 12 57 ± 12 59 ± 16
89 IDC 9 ILC 12 IDC
26.4 ± 14.5 43.1 ± 35.5
40 (44.9%) 5 (41.7%)
2.8 ± 5.4 5.6 ± 10.2
69 (77.5%) 8 (66.7%)
69 (77.5%) 6 (50.0%)
18 (20.2%) 3 (25.0%)
Table 2 List of miRNAs significantly differentially
expressed (corrected p-value < 0.05 and foldchange >2)
between breast cancer and normal serum in the
discovery cohort
MiRNA Foldchange p-value Other serum miRNA











has-miR-155 2.4 0.0078 Roth et al. [24] and Wang et al.
[25] found over-expression of
miR-155 in breast cancer
patients
hsa-miR-126 2.3 <0.0001 Wang et al. [25] found
under-expression of miR-126






Zearo et al. BMC Cancer 2014, 14:200 Page 4 of 7
http://www.biomedcentral.com/1471-2407/14/200compared to the lobular subtype. We chose to concentrate
on miR-484 because it was found to be significantly differ-
entially expressed in cancer versus normal serum in the
validation cohort and there was literature demonstrat-
ing that miR-484 was also differentially expressed in
the serum of pancreatic cancers [13].
We also assessed expression of miR-484 in serum sam-
ples from 8 patients with ovarian cancer but did not find
any difference in expression levels of these miRNAs com-
pared to healthy controls (miR-484: RQ 1.38 p-value 0.88).
There was no correlation between serum levels of either
miR-484 with tumor size, grade, estrogen receptor (ER),Table 3 Results of differentially expressed (foldchange






hsa-miR-195 0.6 0.0002progesterone receptor (PR), human epidermal growth
factor receptor 2 (HER2), axillary lymph node status or
patient age.
Tissue
We assessed the levels of miR-484, miR-21, miR-16 and
U6 snRNA by qPCR on 12 fresh frozen breast cancer
samples and the corresponding matched normal breast
samples. MiR-21 has been frequently reported to be
over-expressed in solid cancers [10]. MiR-16 and U6
snRNA were included as housekeepers. We found that
miR-21 was significantly over-expressed in breast cancer
tissue compared to matched normal tissue (foldchange
4.627, corrected p-value = 0.02), while there was no dif-
ference in expression of miR-484 between breast cancer
and normal tissue samples (Figure 1).
Discussion
The aim of this study was to identify serum miRNAs
that are differentially expressed in serum of early breast
cancer patients compared to healthy volunteers. We found
that miR-484 was significantly differentially expressed in a
discovery cohort of serum from breast cancer patients
compared to healthy volunteers. These results were con-
firmed in a larger validation cohort.
MiR-484 has been identified to be increased in serum
of pancreatic cancer patients. Li et al. compared the
serum of 19 patients with pancreatic cancer compared
to 10 healthy controls. They found 22 miRNAs to be sig-
nificantly differentially expressed between the 2 groups.
They validated 18 of these miRNAs in a different cohort
of serum from 41 pancreatic cancer patients compared toFigure 1 Mean expression of miRNAs relative to U6 in breast
cancer tissue (n = 12) compared to matched normal breast
tissue (n = 12). Expression of miR-21 was significantly higher in
breast cancer tissue compared to normal (p = 0.02) but there was no
difference in miR-484 between the 2 groups. Error bars indicate
standard error of the mean.
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found to be significantly differentially expressed in serum
of pancreatic cancer patients compared to healthy controls
[13]. This indicates that miR-484 is likely associated with a
cancer process but is not specific to breast cancer. Inter-
estingly, Li et al. found that miR-484 was more highly
expressed in microdissected primary pancreatic carcinoma
cells compared to normal pancreatic duct [13]. We did
not however find miR-484 expression to be higher in
breast cancer tissue compared to matched normal breast
tissue in our small sample of 12 patients. MiR-484 expres-
sion in serum did not correlate with outcome in the pan-
creatic cancer patients [13].
We assessed the levels of miR-484 in serum samples
from 8 patients with ovarian cancer. In contrast to the
elevated miR-484 in serum samples of both breast and
pancreatic cancer patients, we did not find a difference
in serum levels of miR-484 in these ovarian cancer pa-
tients compared to healthy controls. These findings may
indicate that miR-484 may be produced as a result of
processes common to both breast and pancreatic cancer,
such as desmoplasia [14,15].
Vecchione et al. found that low expression of miR-484
correlated with chemoresistance in ovarian cancer. Using
in vivo mouse studies with miR-484 stably transduced
ovarian cancer cell lines, more chemosensitive tumors
resulted due to regulation of VEGFB and VEGFR2 by
miR-484. The authors found that miR-484 was secreted
by the ovarian cancer cells to influence the surrounding
tumor-associated endothelial cells [16]. Interestingly,
Volinia et al. performed survival analysis on 466 breast
cancer patients by integrating mRNA, miRNA and DNA
methylation data from TCGA. They found that miR-484
was one of 7 miRNAs and 30 mRNAs which formed an in-
tegrated miRNA/mRNA signature with the highest prog-
nostic value in stage 1 and 2 breast cancers [17]. miR-484
has also been identified as one of the 10 most significantly
up-regulated miRNAs in cutaneous malignant melanoma
compared to benign melanocytic naevi [18].
We did not find higher levels of miR-484 in 12 sam-
ples of breast cancer tissue compared to matched nor-
mal breast tissue, which may be a result of the small
sample size. In line with other reports [4,19], the expres-
sion of miR-21 was found to be significantly higher in
breast cancer tissue compared to matched normal. In
our study, the serum levels of miR-484 did not correlate
with clinicopathological factors of the breast cancer or
patient age. One study reported a correlation between
serum miRNA levels and patient age but not with ER,
PR or HER2 status of the cancer [8] while another study
found correlation between serum miRNA levels with
HER2 status but not ER or PR [20].
The origin of miR-484 in the serum in this study is un-
known. Our results suggest that these miRNAs are notpassively arising from the breast cancer cells. Chan et al.
found that 13 miRNAs were dysregulated in breast
cancer tissue and serum but in opposite direction in-
dicating a selective release of miRNAs from the breast
cancer cells or from other sources [21]. It has been sug-
gested that miRNAs in the circulation arise from 3 pos-
sible sources – either by passive leakage from cells, such
as the cancer cells or other cells including platelets or in-
flammatory cells; through active secretion from the cell
via exosomes or microvesicles; or through active secretion
from the cell via microvesicle-free, RNA-binding protein-
dependent pathway [22]. Kogure et al. studied hepatocel-
lular carcinoma cells and found that miRNAs in exosomes
produced by these cells can be different from those found
within the cell of origin [23].
Van Schooneveld et al. compared serum from 75 breast
cancer patients and 20 healthy volunteers. They found that
miR-299-5p and miR-411 were significantly under-expressed
in breast cancer serum compared to serum from healthy
volunteers, particularly in serum of untreated metastatic
breast cancer patients [8]. Roth et al. studied 59 patients
with early breast cancer, 30 with advanced breast cancer
and 29 healthy volunteers. They found that expression of
miR-10b, miR-34a and miR-155 was higher in breast can-
cer patients compared to healthy volunteers, and miR-10b
and miR-34a in particular were expressed at higher levels
in advanced compared to early breast cancer patients.
They also did not find any correlation between the serum
miRNA levels with histopathological parameters [24]. An-
other group found miR-21, miR-106a and miR-155 to be
over-expressed and miR-126, miR-199a and miR-335 to
be under-expressed in serum of breast cancer patients
compared to healthy controls. This group also found cor-
relation between tumor grade and hormone receptor sta-
tus with expression of serum miRNAs [25]. Interestingly,
across the different studies of serum miRNAs in breast
cancer patients [8,21,24,25] including this study, there has
not been a common miRNA identified which could be in
part due to different RNA extraction methods and plat-
forms used.
We used the TaqMan® Array Human MicroRNA Cards
A and B v3.0 to perform miRNA analysis of our discovery
cohort. Of the 384 miRNAs on card A, we only had
consistent expression of 88 miRNAs. MiRNAs such as
miR-10b, miR-34a and miR-199a which have previously
been identified in other studies to be differentially expressed
in breast cancer serum compared to healthy volunteers
were not expressed in our study. There was very little ex-
pression of the miRNAs on card B. We therefore excluded
card B from analysis.
Interestingly, Hu et al. performed solexa sequencing of
10 samples of pooled serum from lung, breast, cervical,
gastric, hepatocellular carcinoma and healthy volunteers.
They also performed qPCR using 50 other serum samples
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oral, lung and hepatocellular carcinomas as well as
healthy volunteers and found miR-484 levels to be stably
expressed across all samples, leading them to recommend
that miR-484 and miR-191 to be used as endogenous con-
trol for serum miRNA detection [26]. This however has
not been reported by other groups.
Using DIANA-mirPath [27], a software program which
identifies KEGG pathways of miRNA targets, it was found
that miR-484 had 5 predicted targets which were involved
in the adherens junction pathway (p-value = 0.0098). These
included CDH1, the gene which encodes E-cadherin, and
ERBB2, the gene which is amplified in 20-35% of breast
cancer patients [28], both of which are known to be in-
volved in breast tumorigenesis.
Conclusion
In this study, we found that miR-484 is significantly dif-
ferentially expressed between serum of early breast can-
cer patients compared to healthy volunteers. We did not
however find any correlation between miR-484 levels
with histopathological parameters of the breast cancers.
With further studies, miR-484 may prove useful as an
adjunct to mammography for detection of early breast
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